Edition:
India

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

22.50USD
18 Jul 2019
Change (% chg)

$0.24 (+1.08%)
Prev Close
$22.26
Open
$22.20
Day's High
$22.63
Day's Low
$21.89
Volume
221,016
Avg. Vol
234,963
52-wk High
$22.82
52-wk Low
$8.64

Latest Key Developments (Source: Significant Developments)

Fate Therapeutics Reports Qtrly Net Loss Per Common Share $0.30
Wednesday, 8 May 2019 

May 7 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q1 REVENUE $2.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.4 MILLION.FATE THERAPEUTICS - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2019 WERE $183.0 MILLION, COMPARED TO $201.0 MILLION AS OF DECEMBER 31, 2018.QTRLY NET LOSS PER COMMON SHARE $0.30.  Full Article

Fate Therapeutics Reports Q3 Revenue of $1 Million
Friday, 2 Nov 2018 

Nov 1 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q3 REVENUE $1.0 MILLION.Q3 REVENUE VIEW $2.9 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY LOSS PER SHARE $0.31.  Full Article

Ono Pharmaceutical says collaboration with Fate Therapeutics for two iPSC-derived CAR-T Therapies for Cancers
Tuesday, 18 Sep 2018 

Sept 18(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into a collaboration agreement with Fate Therapeutics Inc <<>>, for the joint development and commercialization of two off-the-shelf chimeric antigen receptor(CAR)-T cell product candidates for cancer.  Full Article

Fate Therapeutics Files For Mixed Shelf Of Up To $150 Million
Saturday, 5 May 2018 

May 4 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING.  Full Article

Fate Therapeutics Q4 Loss Per Share $0.29​
Tuesday, 6 Mar 2018 

March 5 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $1.0 MILLION.QTRLY ‍LOSS PER SHARE $0.29​.Q4 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.  Full Article

Fate Therapeutics Announces Pricing Of Public Offering Of Common Stock
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Fate Therapeutics Inc ::FATE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.53 MILLION COMMON SHARES PRICED AT $4.20PER SHARE.  Full Article

Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy
Wednesday, 16 Aug 2017 

Aug 16 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy.Fate Therapeutics Inc - patent covering use of prostaglandins as viral transduction enhancers for genetic modification of cd34hematopoietic cells​.Fate Therapeutics Inc - ‍patent expires in 2029, is owned by Indiana University research and technology corporand is licensed exclusively to co.  Full Article

Fate Therapeutics files for mixed shelf of upto $100 mln
Wednesday, 16 Aug 2017 

Aug 15 (Reuters) - Fate Therapeutics Inc ::Fate Therapeutics Inc files for mixed shelf of upto $100 million - SEC filing.Fate Therapeutics Inc says in addition, selling stockholder may from time to time, offer and sell up to 1 million shares of common stock - SEC filing‍​.Fate Therapeutics Inc says it will not receive any of the proceeds from the sales of common stock from the selling stockholder‍​.  Full Article

Fate Therapeutics Q2 ‍net loss per common share $0.23​
Tuesday, 15 Aug 2017 

Aug 14 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics reports second quarter 2017 financial results.Q2 revenue $1.0 million versus I/B/E/S view $937,000.Fate Therapeutics Inc - qtrly ‍net loss per common share, basic and diluted $0.23​.Q2 earnings per share view $-0.24, revenue view $936600.00 -- Thomson Reuters I/B/E/S.  Full Article

Fate Therapeutics says FDA cleared third IND application for Fate-NK100​
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Fate Therapeutics Inc ::Says ‍U.S. Food and Drug Administration cleared third Investigational New Drug (IND) application for Fate-NK100​.  Full Article